Literature DB >> 9415682

Tandem duplication of 11p12-p13 in a child with borderline development delay and eye abnormalities: dose effect of the PAX6 gene product?

C M Aalfs1, J A Fantes, L J Wenniger-Prick, S Sluijter, R C Hennekam, V van Heyningen, J M Hoovers.   

Abstract

We report on a girl with a duplication of chromosome band 11p12-->13, which includes the Wilms tumor gene (WT1) and the aniridia gene (PAX6). The girl had borderline developmental delay, mild facial anomalies, and eye abnormalities. Eye findings were also present in most of the 11 other published cases with partial trisomy 11p, including 11p12-->13. Recently, it was shown that introduction of additional copies of the PAX6 gene into mice caused very variable eye abnormalities. Therefore, a PAX6 gene dosage effect is likely to be present in mice and humans. The central nervous system may be less sensitive to an altered PAX6 gene dosage, which is consistent with the borderline developmental delay in the present patient. Urogenital abnormalities were absent in this patient and in most of the other patients with partial trisomy of 11p. Therefore, the effect of a WT1 gene duplication on the embryological development of the urogenital tract remains uncertain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415682     DOI: 10.1002/(sici)1096-8628(19971219)73:3<267::aid-ajmg7>3.0.co;2-p

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  15 in total

1.  Overexpression of Pax6 in mouse cornea directly alters corneal epithelial cells: changes in immune function, vascularization, and differentiation.

Authors:  Janine Davis; Joram Piatigorsky
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-13       Impact factor: 4.799

2.  Novel PAX6 binding sites in the human genome and the role of repetitive elements in the evolution of gene regulation.

Authors:  Yi-Hong Zhou; Jessica B Zheng; Xun Gu; Grady F Saunders; W-K Alfred Yung
Journal:  Genome Res       Date:  2002-11       Impact factor: 9.043

3.  A spectrum of FOXC1 mutations suggests gene dosage as a mechanism for developmental defects of the anterior chamber of the eye.

Authors:  D Y Nishimura; C C Searby; W L Alward; D Walton; J E Craig; D A Mackey; K Kawase; A B Kanis; S R Patil; E M Stone; V C Sheffield
Journal:  Am J Hum Genet       Date:  2001-01-18       Impact factor: 11.025

4.  A de novo 11p13 Microduplication in a Patient with Some Features Invoking Silver-Russell Syndrome.

Authors:  O Palumbo; T Mattina; P Palumbo; M Carella; C S Perrotta
Journal:  Mol Syndromol       Date:  2013-11-28

5.  Chromosomal map of human brain malformations.

Authors:  Nataliya Tyshchenko; Iosif Lurie; Albert Schinzel
Journal:  Hum Genet       Date:  2008-06-18       Impact factor: 4.132

6.  Whole-genome copy number variation analysis in anophthalmia and microphthalmia.

Authors:  K F Schilter; L M Reis; A Schneider; T M Bardakjian; O Abdul-Rahman; B A Kozel; H H Zimmerman; U Broeckel; E V Semina
Journal:  Clin Genet       Date:  2013-06-17       Impact factor: 4.438

Review 7.  Chromosome abnormalities and the genetics of congenital corneal opacification.

Authors:  A Mataftsi; L Islam; D Kelberman; J C Sowden; K K Nischal
Journal:  Mol Vis       Date:  2011-06-17       Impact factor: 2.367

8.  Eye anomalies and neurological manifestations in patients with PAX6 mutations.

Authors:  Yin-Hsuan Chien; Hsiang-Po Huang; Wuh-Liang Hwu; Yin-Hsiu Chien; Tseng-Ching Chang; Ni-Chung Lee
Journal:  Mol Vis       Date:  2009-10-22       Impact factor: 2.367

9.  PAX6 dosage effects on corneal development, growth, and wound healing.

Authors:  Natalie Dorà; Jingxing Ou; Romana Kucerova; Ida Parisi; John D West; J Martin Collinson
Journal:  Dev Dyn       Date:  2008-05       Impact factor: 3.780

10.  Effects of elevated Pax6 expression and genetic background on mouse eye development.

Authors:  Simon A Chanas; J Martin Collinson; Thaya Ramaesh; Natalie Dorà; Dirk A Kleinjan; Robert E Hill; John D West
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-22       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.